OCPH Stock Overview
Manufactures and sells pharmaceutical products in Egypt. More details
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 3/6 |
Financial Health | 3/6 |
Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
October Pharma S.A.E Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ج.م107.38 |
52 Week High | ج.م166.99 |
52 Week Low | ج.م83.02 |
Beta | -0.051 |
1 Month Change | -1.61% |
3 Month Change | -6.67% |
1 Year Change | 7.38% |
3 Year Change | 34.23% |
5 Year Change | 144.05% |
Change since IPO | 2,160.63% |
Recent News & Updates
Recent updates
Shareholder Returns
OCPH | EG Pharmaceuticals | EG Market | |
---|---|---|---|
7D | 0% | -1.2% | -0.7% |
1Y | 7.4% | 13.4% | 5.0% |
Return vs Industry: OCPH underperformed the EG Pharmaceuticals industry which returned 15.7% over the past year.
Return vs Market: OCPH matched the EG Market which returned 7% over the past year.
Price Volatility
OCPH volatility | |
---|---|
OCPH Average Weekly Movement | 1.7% |
Pharmaceuticals Industry Average Movement | 5.8% |
Market Average Movement | 5.2% |
10% most volatile stocks in EG Market | 8.3% |
10% least volatile stocks in EG Market | 3.1% |
Stable Share Price: OCPH has not had significant price volatility in the past 3 months compared to the EG market.
Volatility Over Time: OCPH's weekly volatility (2%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1987 | n/a | n/a | www.octoberpharma.com |
October Pharma S.A.E manufactures and sells pharmaceutical products in Egypt. The company provides its products in solid forms, such as tablets, capsules, and powders; liquid forms comprising syrups, drops, solutions, and sprays; creams and suppositories; soft gelatin capsules; and ampoules and vials. October Pharma S.A.E was founded in 1987 is based in Cairo, Egypt.
October Pharma S.A.E Fundamentals Summary
OCPH fundamental statistics | |
---|---|
Market cap | ج.م1.29b |
Earnings (TTM) | ج.م135.37m |
Revenue (TTM) | ج.م1.19b |
9.5x
P/E Ratio1.1x
P/S RatioIs OCPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
OCPH income statement (TTM) | |
---|---|
Revenue | ج.م1.19b |
Cost of Revenue | ج.م664.36m |
Gross Profit | ج.م528.83m |
Other Expenses | ج.م393.46m |
Earnings | ج.م135.37m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 11.28 |
Gross Margin | 44.32% |
Net Profit Margin | 11.35% |
Debt/Equity Ratio | 85.6% |
How did OCPH perform over the long term?
See historical performance and comparisonDividends
2.3%
Current Dividend Yield22%
Payout RatioCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/30 05:57 |
End of Day Share Price | 2025/01/30 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
October Pharma S.A.E is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|